Blog

Corcept Therapeutics CORT announced that it has resubmitted the new drug application (NDA) for its proprietary, selective cortisol modulator, relacorilant, to the FDA as a treatment for patients

Shares of Roper Technologies (ROP) have gained 2.1% over the past four weeks to close the last trading session at $329.97, but there could still be a solid upside left in the stock if short-term

Surgery Partners (SGRY) closed the last trading session at $14.23, gaining 5.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by

Immix Biopharma, Inc. (IMMX) closed the last trading session at $9.13, gaining 2.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by

Shares of Franco-Nevada (FNV) have gained 0.8% over the past four weeks to close the last trading session at $226.93, but there could still be a solid upside left in the stock if short-term price

Mama's Creations, Inc. (MAMA) closed the last trading session at $15.73, gaining 1.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set

From a technical perspective, Insight Enterprises, Inc. (NSIT) is looking like an interesting pick, as it just reached a key level of support. NSIT's 50-day simple moving average crossed above its

Oxford Industries OXM reported first-quarter fiscal 2026 results, marked by stable revenues and stronger-than-expected profitability, even as consumer caution and brand divergence weighed on the

Opendoor Technologies OPEN is showing increasing confidence that it can grow acquisition volumes while maintaining the financial discipline needed to achieve profitability. The company’s

AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will evaluate the irreversible electroporation (IRE) technology delivered by

Biogen BIIB announced that it has entered into a definitive agreement to acquire San Diego-based privately held biotech RayThera Inc. for up to $1 billion. The deal includes an undisclosed upfront

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates

For the quarter ended April 2026, Ulta Beauty (ULTA) reported revenue of $3.16 billion, up 11.1% over the same period last year. EPS came in at $7.74, compared to $6.70 in the year-ago quarter.

The

Construction Partners, Inc. ROAD has established itself as a fast-growing infrastructure contractor, supported by strong public road construction and maintenance demand, resilient DOT spending, and

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different